Da An Gene Completes Early Board Transition; Xu Bin Named Chairman

Da An Gene (SZ002030) held its second extraordinary shareholders' meeting of 2026 on September 14, 2026, approving resolutions on the board transition and electing six non-independent directors and four independent directors to the tenth board. On the same day, the company convened the first extraordinary meeting of the tenth board in 2026, completing the election or appointment of the chairman, vice chairman, members of board committees, senior management and the securities affairs representative, and disclosed the relevant announcements that evening.

The ninth board had originally been due to expire on May 25, 2028. On August 27, 2026, the company held the third meeting of the ninth board, approving resolutions on the early board transition and the nomination of candidates for non-independent and independent directors of the tenth board. The early transition stems from a change in the company's indirect controlling shareholder. According to previous company announcements, Guangzhou Financial Holdings Group and Guangzhou Guangyao Capital have completed the transfer of equity in Guangzhou Guangyong Technology Development, the company's controlling shareholder. On September 11, the company held a staff representative meeting and elected a staff representative director.

The tenth board comprises 11 directors: six non-independent directors, four independent directors and one staff representative director. Xu Bin serves as chairman and Li Xiaodong as vice chairman. He Jianming, Qian Xiang, Zhang Weijie and Liang Zhikun are non-independent directors; Li Han, Fan Jianbing, Liu Huanliang and Zhang Shihong are independent directors; Ye Lili is the staff representative director. The board's term runs for three years from the date the second extraordinary shareholders' meeting of 2026 approved the election.

The company appointed Li Xiaodong as general manager; Qian Xiang, Liang Zhikun, Zhang Weijie, Tan Yanli, Huang Taosheng and Wang Yang as deputy general managers; Qian Xiang concurrently as chief financial officer; Tan Yanli concurrently as board secretary; Shi Lei and Yuan Yifan as assistants to the general manager; and Li Anlin as securities affairs representative.

In this transition, only four of the ten directors of the ninth board remain: Zhang Weijie, Liang Zhikun, Fan Jianbing and Liu Huanliang. Wei Dianhan no longer serves as chairman, non-independent director or member of board committees; Chen Hongwei no longer serves as non-independent director, general manager or member of board committees; Huang Zhizheng no longer serves as non-independent director or head of finance; Zhu Wanyu no longer serves as non-independent director or member of board committees; and Pei Xinchun and Hou Xiangjing no longer serve as independent directors or members of board committees. Zeng Jun no longer serves as board secretary or deputy general manager. The above individuals will not hold other positions at the company after departure. Chen Jie, the ninth board's staff representative director, will continue to hold other positions at the company after leaving office upon expiry of her term.

The new chairman, Xu Bin, male, born in 1977, holds a master of laws degree from Zhongnan University of Economics and Law. He previously served as an assistant judge at the Baiyun District People's Court, director of the office of the Baiyun District Party Committee Organization Department, director of the Party Building Division of the Guangzhou Municipal State-owned Assets Supervision and Administration Commission, and deputy secretary of the Party Committee of Guangzhou Baiyunshan Pharmaceutical Group. He is currently deputy secretary of the Party Committee, chairman of the labor union and a director of Guangzhou Pharmaceutical Group, and Party secretary and chairman of the tenth board of Da An Gene. The new general manager, Li Xiaodong, male, born in 1980, holds a bachelor of science degree from China Pharmaceutical University. He previously served as general manager of the marketing headquarters, Party committee member, director, vice president and executive vice president of Guangzhou Pharmaceutical Company. He is currently deputy secretary of the Party Committee of Da An Gene and a director and general manager of the tenth board.